Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Overview
Overview
Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Key Inclusion Criteria
Key Inclusion Criteria
For a patient to be eligible for participation in this study, all of the following criteria must apply.
- Men or women greater than or equal to 18 years old.
- Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12Cmutation identified through DNA sequencing.
Key Exclusion Criteria
Key Exclusion Criteria
A patient will not be eligible for participation in this study if any of the following criteria apply.
- Active brain metastases from non-brain tumors.
- Myocardial infarction within 6 months of study day 1.
- Gastrointestinal (GI) tract disease causing the inability to take oral medication.
Learn More
Learn More
Contact Us
Contact Us
For more information about this study, please contact Clinical Research at
864-560-6812
Related Locations